Robert Ghenchev

Part of Moelis & Co., Moelis & Co. (UK) LLP is an independent investment bank that provides confidential and unconflicted strategic advice to clients across various industries. The company is based in London, UK. Leveraging their extensive network of 21 geographic locations, the British company delivers the best solutions to their clients. Mark Jonathan Aedy has been the CEO of the company since 2010.

Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets.

Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark.

Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom.

Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets.

Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark.

Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom.

Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom.

Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark.

Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom.

Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom.

Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA.

Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA.

Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom.

Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom.

Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA.

Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA.

Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets.

Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom.

Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA.

Part of Moelis & Co., Moelis & Co. (UK) LLP is an independent investment bank that provides confidential and unconflicted strategic advice to clients across various industries. The company is based in London, UK. Leveraging their extensive network of 21 geographic locations, the British company delivers the best solutions to their clients. Mark Jonathan Aedy has been the CEO of the company since 2010.

Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark.

Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark.

Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA.

Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA.

Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA.

Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark.

Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark.

Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom.

Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA.

Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark.

Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark.

Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark.

Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark.

Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark.

Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA.

Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark.

Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark.

Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark.

Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark.

Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA.

Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark.